Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease
Orphan Drug Designation is awarded to therapies intended to treat rare diseases that affect fewer than 200,000 people in the United States. This designation provides significant benefits, including seven years of market exclusivity upon approval, tax credits for qualified clinical trials, and exemption from certain FDA fees.
'The attainment of Orphan Drug Designation represents an important regulatory milestone for Vascarta and underscores the therapeutic potential of Vasceptor® to provide safe and effective relief to patients living with this debilitating disease,' said Dr. Richard Prince, CEO & President of Vascarta. 'We plan to work closely with the United States Food & Drug Administration to bring Vasceptor® to market as rapidly as possible.'
Dr. Joel Friedman, Professor, Department of Microbiology & Immunology, Albert Einstein College of Medicine, and Vascarta Scientific Founder & Head, Scientific Advisory Board, stated, 'The preclinical results to date showing pain reduction and therapeutic efficacy resulting from our novel approach of targeting red blood cell instability, neuro-inflammation and vascular inflammation bodes well for the development of a widely accessible therapy that prevents and treats many if not most of the clinical consequences of SCD.' Vasceptor® is exclusively licensed to Vascarta from the Albert Einstein College of Medicine (Bronx, New York, USA).
About Vasceptor® (VAS-101)
VAS-101, developed by Vascarta Inc. (Summit, NJ, USA), is a patented topical curcumin formulation that is delivered using patented transdermal technology and that is designed to overcome the limited bioavailability and suboptimal effectiveness of oral dosing of curcumin. A study in PNAS Nexus suggests VAS-101 may reduce chronic pain, stabilize red blood cells, and lower inflammation in sickle cell disease (SCD). It is currently in a Phase 1 clinical trial at the Foundation for Sickle Cell Disease Research (FSCDR) in Hollywood, Florida. While curcumin is known for its safety and anti-inflammatory, antioxidant, and anti-sickling properties, its clinical use has been limited by poor oral bioavailability.
About Sickle Cell Disease
Sickle Cell Disease is the most common inherited genetic disorder that affects primarily African American and non – Hispanic Black individuals in the United States. SCD associated complications include anemia, acute and chronic pain, infections, pneumonia and acute chest syndrome, stroke, kidney, liver, and heart disease.
Current estimates indicate there are 175,000 cases of SCD in the USA and 45,000 in European Union countries. The estimated life expectancy of those with sickle cell disease in the USA is more than 20 years shorter than the average expected lifespan.
SCD is caused by a single point mutation in the globin gene leading to sickling of red blood cells. It is characterized by severe pain, inflammation, oxidative stress, and organ damage, which contributes to the poor quality of life and reduced survival. Recently approved SCD therapies do not mitigate pain, and patients are often on multiple drugs which often have undesirable side effects.
The unmet medical need for most SCD sufferers is significant. Better therapies that are safe, improve outcomes, optimize compliance for patients of all ages, minimize the need for blood transfusions, and reduce the need for chronic administration of potentially harmful pain medications are needed.
About Vascarta
Vascarta Inc. is a clinical stage pharmaceutical company developing efficient transdermal and transmucosal delivery of pharmaceuticals to address inflammatory conditions with an initial focus on Sickle Cell Disease and osteoarthritis. To learn more, contact Vascarta Chairman, CEO & President, Dr. Richard Prince, at rprince@vascarta.com. Media requests should be directed to David Hymson at dhymson@vascarta.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing data and outlines key terms for a future supply agreement for GMP-compliant Monepantel Provides a clear pathway for accelerated global commercialisation of NUZ-001[1] and significantly de-risks future global regulatory approval processes The license agreement represents the first step in formalising Neurizon's relationship with Elanco, with the next step focused on finalising a supply agreement expected H2 CY 2025 MELBOURNE, Australia, July 2, 2025 /PRNewswire/ — Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ('Neurizon' or 'the Company'), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has executed an exclusive global license agreement with Elanco Animal Health Incorporated (Elanco; NYSE: ELAN) and affiliates for Monepantel, the active pharmaceutical ingredient in NUZ-001, Neurizon's lead investigational therapy in development for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases in humans. This license agreement represents a critical inflection point for Neurizon, further strengthening the Company's strategic outlook for the development, manufacturing and potential future commercialisation of NUZ-001. It also significantly supports the Company's regulatory foundations, providing ongoing access to critical animal safety data and manufacturing data, key pillars required to support future clinical trials, potential regulatory approvals and global market entry. Dr. Michael Thurn, Managing Director and Chief Executive Officer, commented: 'This license agreement with Elanco marks a watershed moment in Neurizon's journey to become a leader in the accelerated development of treatments for neurodegenerative diseases. This strategic milestone provides exclusive access to a comprehensive package of non-clinical studies and manufacturing data, dramatically reducing near-term development costs and accelerating development timelines. All of this is in exchange for a nominal up-front payment, small back-ended regulatory approval and commercial sale milestones and single-digit royalty payments on future global net sales. Neurizon is now well-positioned to accelerate the path to market and advance new treatment options for people affected by devastating neurodegenerative diseases.' Mr. Sergio Duchini, Non-Executive Chairman, commented: 'On behalf of the Board, I am pleased to endorse this landmark agreement with Elanco, which represents a strategically significant step forward for Neurizon. This agreement not only strengthens our clinical and regulatory position but also reflects our strong commitment to accelerating the development of meaningful therapies for people living with neurodegenerative diseases. We are also very happy to be making this important step in formalising our relationship with Elanco and look forward to building on this foundation as we progress towards finalising a supply agreement later this year.' Key Terms of the Licensing Agreement: Exclusive Global Rights: Neurizon is granted exclusive global rights to Elanco's data package and related intellectual property for monepantel to develop and commercialise NUZ-001 and its related compounds for the treatment, palliation, prevention, or cure of neurodegenerative diseases in humans. Upfront Payment: A nominal upfront licensing fee is payable to Elanco upon execution of the agreement[2]. Milestone Payments: Total Development milestone payments for the initial and subsequent licensed products, indications, or presentations of US$9.75 million and US$5.2 million, respectively. Elanco will also be eligible for milestone payments of up to US $65 million based on sales milestones[3]. Royalties: Elanco will receive tiered single-digit royalties on global net sales of licensed products. Supply: The agreement outlines certain key terms, including duration and price, for the conclusion of a Supply Agreement. Supply Agreement Neurizon and Elanco remain focused on finalising a supply agreement, with a follow-up announcement anticipated in H2 CY 2025. This next phase of the collaboration is expected to provide Neurizon with long-term, scalable source of GMP-compliant monepantel to support ongoing clinical development, regulatory submissions, and future global commercialisation of NUZ-001. -ENDS- This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited. About Neurizon Therapeutics Limited Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001's potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. Neurizon® is a registered trademark of Neurizon Therapeutics Limited [1] NUZ-001 is Neurizon Therapeutics formulation of monepantel for use in neurodegeneration applications. [2] The amount is not material to Neurizon's current cash position [3] If triggered, the sales milestone payments will not fall due until six months after the first commercial sale. The remaining regulatory and commercial milestone payments will become due 30 days after the relevant milestone is met.
Sinar Daily
19 hours ago
- Sinar Daily
Alliance Bank launches Malaysia's first SME business pitch film to inspire entrepreneurial resilience
SHAH ALAM - Alliance Bank Malaysia Berhad made history with the launch of The Ultimate Elevator Pitch, Malaysia's first feature-length SME business pitch documentary, offering a cinematic portrayal of entrepreneurship. Streaming exclusively on iQIYI from July 18, the film highlights the real-life journeys of 13 entrepreneurs from the 2024 BizSmart® Challenge: Accelerator Edition. In conjunction with World MSME Day, Alliance Bank Malaysia Berhad unveiled The Ultimate Elevator Pitch, a pioneering feature-length documentary spotlighting the entrepreneurial journeys of 13 finalists from the 2024 BizSmart® Challenge. This milestone initiative represents a convergence of business development, cinematic storytelling and digital media, making it the first of its kind in Malaysia. The film, directed by Co-Founder and Chief Executive Officer (CEO) of Ampersand Advisory, Sandeep Joseph, offers rare behind-the-scenes access to high-stakes business pitches, mentorship sessions and the personal challenges encountered by SME founders. The Ultimate Elevator Pitch is available on iQIYI on July 18. "We see entrepreneurs as heroes and that is how we approached this movie. It is raw, relatable and relevant. These are the stories of Malaysia's future business leaders, told without filter," Sandeep said. Alliance Bank Group CEO, Kellee Kam, described the film as a portrait of resilience and ambition. "It is a celebration of the changemakers building our future. For over a decade, we have supported entrepreneurs beyond financial services. This movie invites the public to witness the grit, vulnerability and determination behind Malaysia's SME founders," Kam said. The documentary also serves as a prelude to the 2025 BizSmart® Business Conference (ABBBC), scheduled for Oct 7 at W Kuala Lumpur. Themed "Boundaries Reimagined", the conference will bring together over 35 speakers, including high-growth founders, seasoned investors and BizSmart® alumni such as Timothy Tiah, Winnie Loo, Radius Khor, Mah Jun Kit, Nor Arieni and Dr Jay. Topics will range from cross-border expansion to digital disruption and resilient brand building. The 2024 BizSmart® Challenge marked its 10th anniversary with the introduction of the Accelerator Edition, drawing a record-breaking 593 submissions. It included a multi-stage evaluation; a four-day accelerator programme, a 60-second Elevator Pitch and a final pitch to a panel of industry leaders. Every finalist received a prize, with BioLoop, Gula Cakery, and HiiVolt emerging as the top three, collectively earning a share of RM550,000. Highlighting its role as a pioneer in SME financing, Alliance Bank extended its support through a suite of financial tools beyond conventional banking. These included venture capital via 1337 Ventures and 5X Capital and funding from Cradle's MYStartup and Credit Guarantee Corporation Malaysia Berhad (CGC). In line with current digital consumption trends, the film will stream exclusively on iQIYI. Head of Brand Partnerships, APAC & Middle East at iQIYI Evangeline Song said this was the first time a bank-led SME initiative has been transformed into a cinematic experience that balances heart and ambition. "It highlights the highs, lows and spirit of local founders who are taking bold steps to shape their future," Song said. The idea for The Ultimate Elevator Pitch was sparked by a single insight: entrepreneurship is not just strategy — it is deeply emotional. "This is more than a celebration of success. It is a visual archive and story of what it takes to build a business in today's Malaysia," Sandeep added. Alliance Bank reaffirmed its commitment to inclusive entrepreneurial growth through its early bird promotion for ABBBC 2025, with ticket prices starting at RM88 until July 3. The conference aimed to facilitate networking, business matching and dissemination of strategic insights for SME development. For more information on the BizSmart® Challenge, visit To watch The Ultimate Elevator Pitch, visit iQIYI starting July 18. For details on the 2025 BizSmart® Business Conference, visit
The Sun
a day ago
- The Sun
Drug & Medical Device & Aesthetics, 肌顏態 was displayed at the CSD2025, The GeneQueens and 金因敷 launch was grandly held in Changsha
HONG KONG SAR - EQS Newswire - 2 July 2025 - On June 27, 2025, Uni-Bio Science Group Limited (the 'Group')grandly held a new medical aesthetics product launch event in Changsha, releasing the high-end series GeneQueens of 肌顏態® and the medical device brand 金因敷®. Many experts, KOLs and partners attended the event. This launch not only showcased the Group's achievements in R&D, but also marked the comprehensive layout in the 'drug, medical device and Aesthetics' field. 1、 High-end medical aesthetics: GeneQueens series At the launch, the Group unveiled the high-end series of 肌顏態® -——GeneQueensTM (Human-Sequence Triple Protein Repair & Balance Ampoule). which functions on skin repair and anti-aging. By activating cell regeneration, it helps users restore their youthful and healthy skin condition. GeneQueensTM sets a new standard for anti-aging and repair by adding three core ingredients in sufficient quantities. Skbrella FN, as a key ingredient for cell repair, can accelerate the healing of skin wounds and promote the adhesion and migration of new cells. III Collagen strongly fills the skin structure, significantly enhancing elasticity and firmness. XVII Collagen can strengthen the connection between the epidermis and dermis, and consolidate the youthful foundation of the skin. In addition, GeneQueens adopts a sterile and preservative-free formula, relying on high-purity raw materials and patented technology, providing users with an 'instant enjoyment' precise and efficient experience. Its unique formula and outstanding efficacy were highly recognized by many experts on the spot. 2、金因敷 showcased a variety of new products Meanwhile, the Group also launched several new products of its medical device brand - 金因敷®, focusing on the professional repair field of medical aesthetics. 金因敷® complies with strict clinical trials and quality inspections to ensure its safety and effectiveness. The product adopts a high-purity non-allergenic formula, which can moisturize and accelerate wound repair. It also uses an exclusive cooling technology to relieve postoperative swelling and pain, providing a professional solution for sensitive skin and post-medical procedure care. 3、The latest research data was presented at CSD2025 It is worth mentioning that 肌顏態® also showcased the research data of 'The Efficacy Study of Fibronectin in the Repair of Skin Barrier Damage for the post-medical procedure' jointly conducted with the Cosmetics Testing Center of the Dermatology Hospital of Southern Medical University in the poster area of the 30th Academic Conference of the Chinese Medical Association (CSD2025). This is not only an endorsement of the Group's research capabilities, but also provides experts and scholars in the industry with an opportunity to gain a deeper understanding of the 肌顏態® technology and products. As an annual grand event in the field of dermatology and venereology in China, CSD2025 brings together authoritative experts and scholars in dermatology across the country, presenting multi-dimensional academic achievements and exchanges of ideas. The poster area is one of the core venues of the academic annual conference. Posters are not only an important way for researchers to showcase their scientific research achievements, but also a key link in promoting the dissemination of academic ideas and the feedback of clinical practice. 4、Academic speeches by several experts Several clinical experts at the launch further recognized the significant clinical value of 肌顏態® and 金因敷®. The experts highlighted that 肌顏態®' s patented ingredient, Skbrella FN, demonstrates immense potential in improving damaged sensitive skin barriers, reducing inflammatory erythema, alleviating discomfort sensations such as burning, tightness and itching, as well as enhancing post-laser repair and healing. In the clinical observations over the past few months, many patients treated with 肌顏態® have achieved remarkable therapeutic effects. The symptoms of anesthetic allergy have been rapidly relieved, the inflammatory pigmentation post-laser has significantly improved, the skin barrier has been repaired, and the patient satisfaction rate is extremely high. 金因敷® can effectively reduce redness, swelling and pain for post-medical procedures, accelerate wound healing and shorten the recovery time. Photo 1: 肌顏態 use case sharing by Professor Shi Ge, Director of the Department of Plastic Surgery of the Sixth Affiliated Hospital of Sun Yat-sen University; Photo 2: 肌顏態 use case sharing by Professor Ge Lan, from The First Affiliated Hospital of Army Medical University; Photo 3: Fibronectin clinical trial results sharing by Professor Ye Li, Head of Cosmetics Testing Center at Dermatology Hospital of Southern Medical University; Photo 4: Mr. Du Wei, CEO of Cosmetics News & Cosmetics Business Online, analyzes cosmetics industry development trends 6、The signing ceremony reflects the market potential Mr. Zhao Zhigang, CEO of Uni-Bio Science Group, emphasized: ' We have always adhered to the standards of biopharmaceuticals in creating skin care products. The release of GeneQueens and 金因敷 is an important milestone in building the 'Drugs, Medical device and Aesthetics' strategy and creating a full-cycle skin care solution, aiming to meet consumers' increasingly refined skin health needs. ' Furthermore, Ms. Liu Yihua, President of Global Cosmetics Group, attended the launch as an important guest. Uni-Bio Science Group and Global Cosmetics Group have jointly established a medical research co-creation biological platform. Utilizing gene-editing biosynthesis technology, the platform has launched Skbrella FN – a highly bioactive recombinant human fibronectin known as '皮優理'. The launch also witnessed a grand strategic signing ceremony. The Group has achieved in-depth cooperation with many well-known medical aesthetics chain institutions and well-known agents. This signing is not only a high recognition of the quality and market potential of GeneQueens and 金因敷®, but also a key step for the Group to accelerate commercialization and expand channels. Through strong alliances with leading channel partners, the Group will reach the core consumers and ensure the rapid release of huge commercial value. The successful holding of this launch not only marks a crucial step for the Group in medical aesthetics and medical devices, but also demonstrates the Group's in-depth layout and forward-looking vision in the 'Drugs, Medical device and Aesthetics' strategy. In the future, the Group will continue to be guided by technology and oriented towards clinical value, accelerate product innovation and technological upgrading, constantly enrich pipeline, and meet the growing market demands.
